Skip to main content

Table 3 Characterization of study participants based on serum creatinine measurements during intensive phases of MDR-TB treatment at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia

From: Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Intensive phase of treatment (number of subjects on follow-up) Serum creatinine (mg/dL) (Mean ± SEM) (95% CI) Mean change of serum creatinine from baseline (%) N(%) of participants with >50% increase of serum creatinine from baseline
Baseline (n = 808) 0.75 ± 0.02 [0.71–0.78]
1st month (n = 769) 0.82 ± 0.02 [0.78–0.87] 2.9 83 (10.79)
2nd month (n = 717) 0.85 ± 0.02 [0.81–0.89] 20.67 103 (14.36)
3rd month (n = 661) 0.84 ± 0.01 [0.81–0.88] 13.3 105 (15.88)
4th month (n = 619) 0.86 ± 0.02 [0.81–0.91] 75.6 101 (16.32)
5th month (=582) 0.86 ± 0.02 [0.82–0.91 1.9 90 (15.46)
6th month (n = 533) 0.84 ± 0.01 [0.81–0.88] −33.4 84 (15.75)
7th month (n = 482) 0.82 ± 0.01 [0.80–0.85] −47 76 (15.76)
8th month (n = 415) 0.83 + 0.01 [0.81–0.86] −74.6 75 (18.07)